Damora Therapeutics, Inc. quarterly report, Q2 FY2021

Business Context and Reporting Period

The filing is Galecto, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021, filed August 5, 2021. The request metadata identifies Damora Therapeutics, Inc., but the filing text identifies the registrant as Galecto, Inc. (Nasdaq: GLTO).

Galecto is a clinical-stage biotechnology company developing small-molecule therapies targeting fibrosis and cancer. Its lead candidate is GB0139, an inhaled galectin-3 inhibitor being evaluated in idiopathic pulmonary fibrosis (IPF). Other candidates include GB2064 for myelofibrosis and GB1211 for non-small cell lung cancer and liver cirrhosis.

Financial Metrics

MetricThree Months Ended June 30, 2021Six Months Ended June 30, 2021
RevenueNo product revenueNo product revenue
Research and development expense$8.6 million$18.6 million
General and administrative expense$3.6 million$7.2 million
Total operating expenses$12.3 million$25.8 million
Net loss$12.3 million$25.6 million
Net loss per share$0.49$1.02
Net cash used in operating activitiesNot separately provided$25.3 million
  • Cash and cash equivalents were $68.6 million at June 30, 2021.
  • Current and long-term marketable securities totaled $69.0 million, producing cash, cash equivalents and marketable securities of $137.7 million.
  • Total assets were $146.8 million, total liabilities were $5.4 million, and stockholders’ equity was $141.4 million.
  • Accumulated deficit was $130.0 million.
  • There was no debt disclosed; liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities.
  • Net cash used in investing activities was $69.5 million, principally reflecting purchases of marketable securities.
  • There were no financing cash flows during the six months ended June 30, 2021.
  • The company had $1.2 million of future lease payments recorded as contractual obligations at June 30, 2021.

Material Changes Versus the Prior Comparable Period

  • Three-month research and development expense increased 91.3% to $8.6 million, primarily because of higher clinical trial activity and personnel costs.
  • Three-month general and administrative expense increased 99.3% to $3.6 million, driven by higher insurance, headcount, stock-based compensation and consulting costs.
  • Six-month research and development expense increased 102.0% to $18.6 million, reflecting higher clinical trial expenses, chemistry, manufacturing and control activities, personnel and consulting costs.
  • Six-month general and administrative expense increased 144.2% to $7.2 million.
  • Six-month net loss increased 120.9% from $11.6 million to $25.6 million.
  • Operating cash use increased from $15.1 million to $25.3 million.
  • The company invested excess cash in marketable securities during 2021; it held no marketable securities at December 31, 2020.
  • Stock-based compensation increased to $2.0 million for the first six months of 2021 from $0.4 million in the prior-year period.

Guidance, Outlook, Risks and Unusual Items

  • Management expects continued operating losses and increasing research and development, general and administrative and capital expenditures.
  • Based on its current operating plan, management expects $137.7 million of cash, cash equivalents and marketable securities at June 30, 2021 to fund operations into the second half of 2024. This estimate depends on assumptions that may prove inaccurate.
  • The GALACTIC-1 Phase 2b trial of GB0139 was modified after the data safety monitoring board identified an imbalance in serious adverse events across study groups, although not an imbalance in mortality. Dosing was discontinued for patients receiving nintedanib or pirfenidone and for the 10 mg dose.
  • Recruitment resumed in July 2021 under a revised design evaluating 3 mg GB0139 versus placebo. Topline results are expected by mid-2023.
  • The planned MYLOX-1 Phase 2a trial of GB2064 was expected to begin in the third quarter of 2021, with topline results expected by the end of 2022.
  • Management expected to initiate the GULLIVER-2 trial of GB1211 in liver cirrhosis later in 2021 and the GALLANT-1 trial in combination with an anti-PD-1/PD-L1 therapy for non-small cell lung cancer in the first half of 2022.
  • COVID-19 had delayed patient recruitment and the initiation of certain planned clinical trials. Additional disruptions to enrollment, supply chains and operations remained possible.
  • The company has not generated product revenue and will require additional capital or strategic transactions to fund operations beyond its current cash runway. Potential financing could dilute existing stockholders or impose debt-related restrictions.
  • Management concluded that disclosure controls and procedures were not effective as of June 30, 2021 because of previously reported material weaknesses in internal control over financial reporting.
  • The filing states there were no material changes to previously disclosed risk factors, no material legal proceedings and no subsequent events requiring disclosure.

Important Facts for Investors to Verify

  • Confirm the registrant identity: the supplied filing is for Galecto, Inc., not Damora Therapeutics, Inc.
  • Verify the revised GALACTIC-1 protocol, serious-adverse-event imbalance and timing of expected GB0139 results.
  • Assess whether the projected cash runway into the second half of 2024 remains supported by current spending and trial plans.
  • Monitor the need for future equity, debt, licensing or collaboration financing and the related dilution or restrictions.
  • Review the material weaknesses in internal control over financial reporting and any remediation progress.
  • Evaluate clinical, regulatory, manufacturing, intellectual-property and COVID-19 execution risks for GB0139, GB2064 and GB1211.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.